Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

105.92 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9
Open 105.92
Bid (Size) 105.42 (1)
Ask (Size) 106.54 (1)
Prev. Close 105.92
Today's Range 105.92 - 105.92
52wk Range 81.64 - 115.49
Shares Outstanding 2,531,374,696
Dividend Yield 2.45%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
11 Stocks: 9 Dividend Payers 2 For Growth
Not all stocks are the same, and not all stocks serve the investor’s needs. 
Via Talk Markets
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
-4.70%
-4.70%
1 Month
-0.30%
-0.30%
3 Month
-4.42%
-4.42%
6 Month
+22.25%
+22.25%
1 Year
+28.54%
+28.54%

More News

Read More
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
From Merck & Co., Inc.
Via Business Wire
Merck & Co Unusual Options Activity For March 29
Via Benzinga
Merck Releases Keytruda Data In Frontline Endometrial Cancer Patients
Via Benzinga
Is the Best-Performing Dow Stock of the Past Year a Buy?
Via The Motley Fool
Could This Be Merck's Next Blockbuster Drug?
Via The Motley Fool
Moderna's CEO Just Gave Investors a Huge Reason to Sell the Stock
Via The Motley Fool
Don't Be Fooled by These 3 Value Traps
Via MarketBeat
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
From Merck & Co., Inc.
Via Business Wire
A Look Into Merck & Co's Debt
Via Benzinga
BioNTech Is Ripe For A Rebound In 2023
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence
Via The Motley Fool
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
Via InvestorPlace
7 Defensive Stocks to Buy During This Chaotic Spell
Via InvestorPlace
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
Via Benzinga
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
This High-Growth Company Is Expanding. Time to Buy the Stock?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
Via MarketBeat
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
Via Benzinga
Stock Market Tumbles Amid SVB Financial Collapse, 'Faster' Powell: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.